Akso Health Group (AHG) P/E Ratio History
Historical price-to-earnings valuation from 2018 to 2023
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, Akso Health Group (AHG) trades at a price-to-earnings ratio of -3.0x, with a stock price of $1.43 and trailing twelve-month earnings per share of $-0.40.
The current P/E is 142% below its 5-year average of 7.1x. Over the past five years, AHG's P/E has ranged from a low of 0.0x to a high of 58.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Financial Services sector median P/E of 13.8x, AHG trades at a 122% discount to its sector peers. The sector includes 789 companies with P/E ratios ranging from 0.0x to 196.2x.
Relative to the broader market, AHG trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AHG DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Consumer Credit Issuers and Installment Lenders peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
COFCapital One Financial Corporation | $124B | 16.9 | - | -3% |
SYFSynchrony Financial | $25B | 8.1 | 0.90 | +65%Best |
SYF-PBSynchrony Financial | $9B | 3.1 | 0.34 | +65%Best |
OMFOneMain Holdings, Inc. | $7B | 8.4 | 2.13 | +55% |
ENVAEnova International, Inc. | $3B | 12.0 | - | +56% |
FINVFinVolution Group | $3B | 4.3 | 1.25 | +8% |
BFHBread Financial Holdings, Inc. | $3B | 12.9 | - | -62% |
LULufax Holding Ltd | $2B | 5.8 | - | -90% |
XYFX Financial | $1B | 0.2Lowest | 0.00Best | +29% |
ATLCAtlanticus Holdings Corporation | $791M | 11.0 | 0.47 | +13% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q3 | Sat Dec 31 2022 00:00:00 GM | $0.38 | $1.48 | 0.3x | -96% |
| FY2023 Q2 | Fri Sep 30 2022 00:00:00 GM | $0.91 | $1.78 | 0.5x | -93% |
| FY2023 Q1 | $1.02 | $4.67 | 0.2x | -97% | |
| FY2022 Q4 | $1.69 | $3.78 | 0.4x | -94% | |
| FY2021 Q3 | $2.47 | $12375.96 | 0.0x | -100% | |
| FY2021 Q2 | Wed Sep 30 2020 00:00:00 GM | $1.48 | $12372.93 | 0.0x | -100% |
| FY2021 Q1 | $2.42 | $12368.01 | 0.0x | -100% | |
| FY2020 Q4 | $3.78 | $12368.31 | 0.0x | -100% | |
| FY2019 Q4 | Sun Mar 31 2019 00:00:00 GM | $30.06 | $0.51 | 58.9x | +726% |
| FY2019 Q3 | Mon Dec 31 2018 00:00:00 GM | $22.50 | $2.94 | 7.7x | +7% |
| FY2019 Q2 | Sun Sep 30 2018 00:00:00 GM | $70.92 | $9.39 | 7.6x | +6% |
| FY2019 Q1 | Sat Jun 30 2018 00:00:00 GM | $90.54 | $15.27 | 5.9x | -17% |
Average P/E for displayed period: 7.1x
See AHG's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AHG Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare AHG vs JPM
See how AHG stacks up against sector leader JPMorgan Chase & Co..
Start ComparisonFrequently Asked Questions
Is AHG stock overvalued or undervalued?
AHG trades at -3.0x P/E, below its 5-year average of 7.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does AHG's valuation compare to peers?
Akso Health Group P/E of -3.0x compares to sector median of 13.8x. The discount suggests lower growth expectations or higher risk.
What is AHG's PEG ratio?
AHG PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2018-2023.